CHST7 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NS84 |
---|---|
Clone Names | 90904083 |
Gene ID | 56548 |
---|---|
Other Names | Carbohydrate sulfotransferase 7, 282-, Chondroitin 6-sulfotransferase 2, C6ST-2, Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 5, GST-5, N-acetylglucosamine 6-O-sulfotransferase 4, GlcNAc6ST-4, Gn6st-4, CHST7 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP9158c was selected from the Center region of human CHST7. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CHST7 |
---|---|
Function | Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues. Preferentially acts on mannose-linked GlcNAc. Also able to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Also acts on core 2 mucin-type oligosaccharide and N-acetyllactosamine oligomer with a lower efficiency. Has weak or no activity toward keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc. Catalyzes 6-O-sulfation of beta-benzyl GlcNAc but not alpha- or beta-benzyl GalNAc. |
Cellular Location | Golgi apparatus membrane; Single- pass type II membrane protein |
Tissue Location | Widely expressed. Highly expressed in heart, spleen, liver and ovary. Expressed at lower level in brain, placenta, thyroid, spinal cord and peripheral blood leukocytes. Not expressed in adult skin. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CHST7 catalyzes the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues. It preferentially acts on mannose-linked GlcNAc and also able to catalyze the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. It also acts on core 2 mucin-type oligosaccharide and N-acetyllactosamine oligomer with a lower efficiency. This protein has weak or no activity toward keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc. It catalyzes 6-O-sulfation of beta-benzyl GlcNAc but not alpha-or beta-benzyl GalNAc.
References
Liu T., et.al., J. Proteome Res. 4:2070-2080(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.